Truist Financial Lowers Elevance Health (NYSE:ELV) Price Target to $390.00

Elevance Health (NYSE:ELV) had its target price cut by investment analysts at Truist Financial from $400.00 to $390.00 in a research note issued on Monday, Marketbeat Ratings reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price target indicates a potential upside of 15.16% from the company’s current price.

Several other research firms have also recently issued reports on ELV. Robert W. Baird upped their price target on Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. UBS Group set a $400.00 target price on Elevance Health in a research report on Thursday, January 29th. Leerink Partners upped their target price on Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a report on Thursday, January 29th. Morgan Stanley dropped their price target on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 17th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Elevance Health from $384.00 to $394.00 and gave the company an “overweight” rating in a research note on Tuesday, October 28th. Twelve research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Trading Down 0.9%

Shares of Elevance Health stock opened at $338.66 on Monday. The business has a fifty day simple moving average of $351.99 and a 200-day simple moving average of $329.59. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The firm has a market cap of $75.26 billion, a price-to-earnings ratio of 13.48, a price-to-earnings-growth ratio of 1.90 and a beta of 0.50. The company has a quick ratio of 1.56, a current ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. During the same period in the previous year, the business earned $3.84 earnings per share. Elevance Health’s revenue for the quarter was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts forecast that Elevance Health will post 33.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ELV. Physician Wealth Advisors Inc. grew its holdings in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after acquiring an additional 63 shares in the last quarter. Activest Wealth Management grew its stake in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares in the last quarter. Rossby Financial LCC increased its position in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares during the last quarter. Vermillion & White Wealth Management Group LLC raised its stake in shares of Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after purchasing an additional 37 shares in the last quarter. Finally, BOK Financial Private Wealth Inc. acquired a new stake in shares of Elevance Health during the 2nd quarter valued at about $32,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: JPMorgan raised its price target slightly from $394 to $397 and maintained an “overweight” rating, which supports upside vs. the current price. Read More.
• Neutral Sentiment: Options-market activity is drawing attention — some traders see positioning that could presage larger moves, but this is speculative and not a direct fundamental change. Read More.
• Neutral Sentiment: Seeking Alpha published a long-form take (“It Has Been Painful, But This Too Shall Pass”) arguing the near-term weakness is cyclical and could reverse — useful for longer-term investors but less likely to move stock intraday. Read More.
• Neutral Sentiment: The Globe and Mail aggregated analyst commentary on multiple healthcare names including Elevance; helpful context but no single decisive call. Read More.
• Negative Sentiment: RBC downgraded ELV from “outperform” to “sector perform” and set a $358 target — a downgrade in stance that likely pressured sentiment despite a modestly positive target. Read More.
• Negative Sentiment: Truist trimmed its price target from $400 to $390 while keeping a “buy” rating — the lower target reduces upside expectations and can weigh on the stock. Read More.
• Negative Sentiment: Jefferies cut its price target to $395, another downward revision that adds to the negative analyst tone. Read More.
• Negative Sentiment: Sanford C. Bernstein lowered its target to $409 — still above the current price but a cut nonetheless, contributing to the cluster of downward revisions. Read More.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.